PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model

Free Radical Biology and Medicine

Volumn 80, Issue , 2015, Pages 136-144

  Yun, Hyung Mun ^a   Park, Kyung Ran ^a   Park, Mi Hee ^b   Kim, Dae Hwan ^b   Jo, Mi Ran ^b   Kim, Ji Young ^b   Kim, Eun Cheol ^a   Yoon, Do Young ^c   Han, Sang Bae ^b   Hong, Jin Tae ^b  

^a Kyung Hee University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

Free radicals; GPx; iPLA2; JAK2; Lung cancer; PRDX6; STAT3

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 5; PEROXIREDOXIN 6; RANTES; STAT3 PROTEIN; URETHAN; CCL5 PROTEIN, MOUSE; CCR5 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR5; DNA; JAK2 PROTEIN, MOUSE; PHOSPHOLIPASE A2 GROUP VI; PLA2G6 PROTEIN, MOUSE; PRDX6 PROTEIN, MOUSE; PROTEIN BINDING; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; CHEMOKINE CCL5; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; GROUP VI PHOSPHOLIPASES A2; INJECTIONS, INTRAPERITONEAL; JANUS KINASE 2; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEROXIREDOXIN VI; PROTEIN BINDING; RECEPTORS, CCR5; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; URETHANE;

EID: 84922251110     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.12.022     Document Type: Article

References (62)

1. Chen, Z.; Wang, T.; Cai, L.; Su, C.; Zhong, B.; Lei, Y.; Xiang, A. P. Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res 31:10; 2012.
2. Saintigny, P.; Burger, J. A. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13:287-297; 2012.
3. Garbuzenko, O. B.; Saad, M.; Pozharov, V. P.; Reuhl, K. R.; Mainelis, G.; Minko, T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 107:10737-10742; 2010.
4. Filosto, S.; Becker, C. R.; Goldkorn, T. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther 11:795-804; 2012.
5. Bauer, A. K.; Cho, H. Y.; Miller-Degraff, L.; Walker, C.; Helms, K.; Fostel, J.; Yamamoto, M.; Kleeberger, S. R. Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice. PLoS One 6:e26590; 2011.
6. Kamata, T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100:1382-1388; 2009.
7. Rhee, S. G.; Kang, S. W.; Chang, T. S.; Jeong, W.; Kim, K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52:35-41; 2001.
8. Wood, Z. A.; Schroder, E.; Robin Harris, J.; Poole, L. B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28:32-40; 2003.
9. Chowdhury, I.; Mo, Y.; Gao, L.; Kazi, A.; Fisher, A. B.; Feinstein, S. I. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic Biol Med 46:146-153; 2009.
10. Ho, J. N.; Lee, S. B.; Lee, S. S.; Yoon, S. H.; Kang, G. Y.; Hwang, S. G.; Um, H. D. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther 9:825-832; 2010.
11. Pak, J. H.; Choi, W. H.; Lee, H. M.; Joo, W. D.; Kim, J. H.; Kim, Y. T.; Kim, Y. M.; Nam, J. H. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 29:21-28; 2011.
12. Chang, X. Z.; Li, D. Q.; Hou, Y. F.; Wu, J.; Lu, J. S.; Di, G. H.; Jin, W.; Ou, Z. L.; Shen, Z. Z.; Shao, Z. M. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9:R76; 2007.
13. Kinnula, V. L.; Lehtonen, S.; Sormunen, R.; Kaarteenaho-Wiik, R.; Kang, S. W.; Rhee, S. G.; Soini, Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196:316-323; 2002.
14. Lehtonen, S. T.; Svensk, A. M.; Soini, Y.; Paakko, P.; Hirvikoski, P.; Kang, S. W.; Saily, M.; Kinnula, V. L. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111:514-521; 2004.
15. Kim, S. Y.; Jo, H. Y.; Kim, M. H.; Cha, Y. Y.; Choi, S. W.; Shim, J. H.; Kim, T. J.; Lee, K. Y. H2O2-dependent hyperoxidation of peroxiredoxin 6 (Prdx6) plays a role in cellular toxicity via up-regulation of iPLA2 activity. J Biol Chem 283:33563-33568; 2008.
16. Kim, S. Y.; Chun, E.; Lee, K. Y. Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis. Cell Death Differ 18:1573-1583; 2011.
17. Wang, X.; Phelan, S. A.; Forsman-Semb, K.; Taylor, E. F.; Petros, C.; Brown, A.; Lerner, C. P.; Paigen, B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 278:25179-25190; 2003.
18. Wang, Y.; Phelan, S. A.; Manevich, Y.; Feinstein, S. I.; Fisher, A. B. Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia. Am J Respir Cell Mol Biol 34:481-486; 2006.
19. Jo, M.; Yun, H. M.; Park, K. R.; Hee Park, M.; Myoung Kim, T.; Ho Pak, J.; Jae Lee, S.; Moon, D. C.; Park, C. W.; Song, S.; Lee, C. K.; Bae Han, S.; Tae Hong, J. Lung tumor growth-promoting function of peroxiredoxin 6. Free Radic Biol Med 61C:453-463; 2013.
20. Yun, H. M.; Park, K. R.; Lee, H. P.; Lee, D. H.; Jo, M.; Shin, D. H.; Yoon, D. Y.; Han, S. B.; Hong, J. T. PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities. Free Radic Biol Med 69C:367-376; 2014.
21. Darnell Jr. J.E. STATs and gene regulation. Science 277:1630-1635; 1997.
22. Avalle, L.; Pensa, S.; Regis, G.; Novelli, F.; Poli, V. STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT 1:65-72; 2012.
23. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54; 2004.
24. Madoux, F.; Koenig, M.; Nelson, E.; Chowdhury, S.; Cameron, M.; Mercer, B.; Roush, W.; Frank, D.; Hodder, P. Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Activators). 2010.
25. Bromberg, J. F.; Wrzeszczynska, M. H.; Devgan, G.; Zhao, Y.; Pestell, R. G.; Albanese, C.; Darnell Jr. J.E. Stat3 as an oncogene. Cell 98:295-303; 1999.
26. Sun, H.; Zhang, Y.; Gao, P.; Li, Q.; Sun, Y.; Zhang, J.; Xu, C. Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol Cell Biochem 347:183-189; 2011.
27. Yeh, C. T.; Huang, W. C.; Rao, Y. K.; Ye, M.; Lee, W. H.; Wang, L. S.; Tzeng, D. T.; Wu, C. H.; Shieh, Y. S.; Huang, C. Y.; Chen, Y. J.; Hsiao, M.; Wu, A. T.; Yang, Z.; Tzeng, Y. M. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells. Carcinogenesis 34:2918-2928; 2013.
28. Lee, N. J.; Choi, D. Y.; Song, J. K.; Jung, Y. Y.; Kim, D. H.; Kim, T. M.; Kim, D. J.; Kwon, S. M.; Kim, K. B.; Choi, K. E.; Moon, D. C.; Kim, Y.; Han, S. B.; Hong, J. T. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model. Carcinogenesis 33:2520-2528; 2012.
29. Chatterjee, S.; Feinstein, S. I.; Dodia, C.; Sorokina, E.; Lien, Y. C.; Nguyen, S.; Debolt, K.; Speicher, D.; Fisher, A. B. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. J Biol Chem 286:11696-11706; 2011.
30. Yun, H. M.; Kim, S.; Kim, H. J.; Kostenis, E.; Kim, J. I.; Seong, J. Y.; Baik, J. H.; Rhim, H. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem 282:5496-5505; 2007.
31. Yun, H. M.; Baik, J. H.; Kang, I.; Jin, C.; Rhim, H. Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J Biol Chem 285:10016-10029; 2010.
32. Yun, H. M.; Park, K. R.; Lee, H. P.; Lee, D. H.; Jo, M.; Shin, D. H.; Yoon, D. Y.; Han, S. B.; Hong, J. T. PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities. Free Radic Biol Med 69:367-376; 2014.
33. Zhang, X. Z.; Xiao, Z. F.; Li, C.; Xiao, Z. Q.; Yang, F.; Li, D. J.; Li, M. Y.; Li, F.; Chen, Z. C. Triosephosphate isomerase and peroxiredoxin 6,two novel serum markers for human lung squamous cell carcinoma. Cancer Sci 100:2396-2401; 2009.
34. Manevich, Y.; Reddy, K. S.; Shuvaeva, T.; Feinstein, S. I.; Fisher, A. B. Structure and phospholipase function of peroxiredoxin 6: identification of the catalytic triad and its role in phospholipid substrate binding. J Lipid Res 48:2306-2318; 2007.
35. Walsh, B.; Pearl, A.; Suchy, S.; Tartaglio, J.; Visco, K.; Phelan, S. A. Overexpression of Prdx6 and resistance to peroxide-induced death in Hepa1-6 cells: Prdx suppression increases apoptosis. Redox Rep 14:275-284; 2009.
36. Lee, S. B.; Ho, J. N.; Yoon, S. H.; Kang, G. Y.; Hwang, S. G.; Um, H. D. Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. Mol Cells 28:583-588 2009.
37. Qin, L.; Liao, L.; Redmond, A.; Young, L.; Yuan, Y.; Chen, H.; O'Malley, B. W.; Xu, J. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28:5937-5950; 2008.
38. Chen, Q.; Li, W.; Wan, Y.; Xia, X.; Wu, Q.; Chen, Y.; Lai, Z.; Yu, C. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 55:1820-1829; 2012.
39. Fisher, A.B. Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A(2) activities. Antioxid Redox Signal 15:831- 844; 2011.
40. Chen, J. W.; Dodia, C.; Feinstein, S. I.; Jain, M. K.; Fisher, A. B. 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J Biol Chem 275:28421-28427; 2000.
41. Fong, Y.; Shen, K. H.; Chiang, T. A.; Shih, Y. W. Acacetin inhibits TPA-induced MMP-2 and u-PA expressions of human lung cancer cells through inactivating JNK signaling pathway and reducing binding activities of NF-kappaB and AP-1. J Food Sci 75:H30-38; 2010.
42. Wang, L.; Chanvorachote, P.; Toledo, D.; Stehlik, C.; Mercer, R. R.; Castranova, V.; Rojanasakul, Y. Peroxide is a key mediator of Bcl-2 down-regulation and apoptosis induction by cisplatin in human lung cancer cells. Mol Pharmacol 73:119-127; 2008.
43. McHowat, J.; Gullickson, G.; Hoover, R. G.; Sharma, J.; Turk, J.; Kornbluth, J. Platelet-activating factor and metastasis: calcium-independent phospholipase A2beta deficiency protects against breast cancer metastasis to the lung. Am J Physiol Cell Physiol 300:C825-832; 2011.
44. Alvarez, J. V.; Febbo, P. G.; Ramaswamy, S.; Loda, M.; Richardson, A.; Frank, D. A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65:5054-5062; 2005.
45. Fossey, S. L.; Liao, A. T.; McCleese, J. K.; Bear, M. D.; Lin, J.; Li, P. K.; Kisseberth, W. C.; London, C. A. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 9:81; 2009.
46. Haura, E. B.; Turkson, J.; Jove, R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2:315-324; 2005.
47. Chen, J. Y.; Luo, B.; Guo, X. B.; Wan, L. H. [Double suicide gene therapy with RNAi targeting to STAT3 inhibits the growth of colorectal carcinoma cells in vitro]. Zhonghua Zhong Liu Za Zhi 33:91-96; 2011.
48. Chen, K. F.; Tai, W. T.; Huang, J. W.; Hsu, C. Y.; Chen, W. L.; Cheng, A. L.; Chen, P. J.; Shiau, C. W. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem 46:2845-2851; 2011.
49. Ai, T.; Wang, Z.; Zhang, M.; Zhang, L.; Wang, N.; Li, W.; Song, L. Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer. Int J Biol Markers 27:e132-e138; 2012.
50. Jiang, R.; Jin, Z.; Liu, Z.; Sun, L.; Wang, L.; Li, K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 15:347-352; 2011.
51. Jo, M.; Park, M. H.; Kollipara, P. S.; An, B. J.; Song, H. S.; Han, S. B.; Kim, J. H.; Song, M. J.; Hong, J. T. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol 258:72-81; 2012.
52. Raman, D.; Sobolik-Delmaire, T.; Richmond, A. Chemokines in health and disease. Exp Cell Res 317:575-589; 2011.
53. Wong, M. M.; Fish, E. N. Chemokines: attractive mediators of the immune response. Semin Immunol 15:5-14; 2003.
54. Aldinucci, D.; Colombatti, A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm 2014:292376; 2014.
55. Kim, J. E.; Kim, H. S.; Shin, Y. J.; Lee, C. S.; Won, C.; Lee, S. A.; Lee, J. W.; Kim, Y.; Kang, J. S.; Ye, S. K.; Chung, M. H. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med 40:514-522; 2008.
56. Wang, S. W.; Wu, H. H.; Liu, S. C.; Wang, P. C.; Ou, W. C.; Chou, W. Y.; Shen, Y. S.; Tang, C. H. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 7:e35101; 2012.
57. Li, G.; Zhu, G.; Gao, Y.; Xiao, W.; Xu, H.; Liu, S.; Tu, G.; Peng, H.; Zheng, C.; Liang, S. Neferine inhibits the upregulation of CCL5 and CCR5 in vascular endothelial cells during chronic high glucose treatment. Inflammation 36:300-308; 2013.
58. Huang, C. Y.; Fong, Y. C.; Lee, C. Y.; Chen, M. Y.; Tsai, H. C.; Hsu, H. C.; Tang, C. H. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol 77:794-803; 2009.
59. Wong, M.; Uddin, S.; Majchrzak, B.; Huynh, T.; Proudfoot, A. E.; Platanias, L. C.; Fish, E. N. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 276:11427-11431; 2001.
60. Fu, X. Y. A transcription factor with SH2 and SH3 domains is directly activated by an interferon alpha-induced cytoplasmic protein tyrosine kinase(s). Cell 70:323-335; 1992.
61. Darnell Jr. J.E. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 18:549-554; 1998.
62. Wong, M.; Fish, E. N. RANTES and MIP-1alpha activate stats in T cells. J Biol Chem 273:309-314; 1998.